GlassScriptPhysician profile
Emily R Emmet
NPI 1487617569
$15,421.80
in general payments reported to CMS, 2019-2025
29 companies · $7,621 in 2025
The $7,621 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $46.93 · 2022: $25.66 · 2023: $3,013 · 2024: $4,345 · 2025: $7,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Education: $1,500 · Food and Beverage: $1,061 · Travel and Lodging: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,400.00 |
| Education | $1,500.00 |
| Food and Beverage | $1,060.54 |
| Travel and Lodging | $1,018.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $11,406.01 | 2024-2025 | Bovine Collagen |
| Intuitive Surgical, INC. | $2,518.32 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Mayne Pharma Commercial LLC | $220.76 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $122.79 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $110.41 | 2023-2025 | Slynd |
| Millicent US INC | $99.87 | 2019-2024 | Intrarosa |
| Abbvie INC. | $89.27 | 2019-2023 | |
| Pfizer INC. | $79.89 | 2019-2024 | |
| Astellas Pharma US INC | $78.58 | 2023-2025 | Veozah |
| Organon LLC | $67.50 | 2024-2025 | Nexplanon |
| Novo Nordisk INC | $65.40 | 2023-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $64.84 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $47.99 | 2019-2020 | |
| Allergan, INC. | $43.48 | 2019 | |
| Minerva Surgical, INC | $41.84 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $39.92 | 2023-2024 | |
| Lupin INC. | $37.68 | 2019 | |
| Therapeuticsmd, INC. | $34.03 | 2019-2020 | |
| Dilon Technologies, INC. | $34.01 | 2025 | Hemoblast Bellows |
| Hologic Sales and Service, LLC | $32.83 | 2024 | Novasure, Myosure Tissue Removal Device, Coolseal Generator |
| Mission Pharmacal Company | $29.36 | 2019 | |
| Covidien LP | $25.08 | 2019 | |
| Daiichi Sankyo INC. | $23.41 | 2023 | Injectafer |
| Shield Therapeutics INC | $23.13 | 2024 | |
| Avanos Medical | $19.18 | 2019 | |
| Smith+Nephew, INC. | $18.48 | 2019 | |
| Conmed Corporation | $17.55 | 2025 | Airseal |
| Convatec INC. | $16.29 | 2023 | |
| Meditrina | $13.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Emmet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.